In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA)

This publication has 23 references indexed in Scilit:

• K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine
  Antimicrobial Agents and Chemotherapy, 1995
• Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine
  Antimicrobial Agents and Chemotherapy, 1994
• Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.
  Journal of Clinical Investigation, 1993
• Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group
  Antimicrobial Agents and Chemotherapy, 1993
• Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine
  Antimicrobial Agents and Chemotherapy, 1993
• 9-(2-phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys
  AIDS, 1991
• Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy
  The Lancet, 1990
• Anti‐retrovirus activity of 9‐(2‐phosphonylmethoxyethyl)adenine (pmea) in vivo increases when it is less frequently administered
  International Journal of Cancer, 1990
• A novel selective broad-spectrum anti-DNA virus agent
  Nature, 1986
• Infection of HTLV-III/LAV in HTLV-I-Carrying Cells MT-2 and MT-4 and Application in a Plaque Assay
  Science, 1985